retrospectively reviewed 237 IgA nephropathy cases diagnosed from 1981 ... pathologic data revealed serum creatinine level, urinary protein excretion, mean arterial blood pressure, and age at ...

IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their ...

In a phase 2 study, iptacopan — an oral, highly potent proximal complement inhibitor — reduced proteinuria in patients with IgA nephropathy. New research findings from a phase 3 trial are ...

Patients with IgA nephropathy and severe proteinuria have a high lifetime risk of kidney failure. New research findings on the efficacy and safety of the selective endothelin type A receptor ...

A urine test may also reveal protein levels in your urine that suggest chronic kidney disease. If you receive a diagnosis of IgA nephropathy at this early stage, there is time to slow kidney ...

Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 353 , 883–887 (1999). Article CAS Google Scholar ...

The new data – in rare kidney disease IgA nephropathy (IgAN ... statistically significant" reduction in the levels of protein in the urine (proteinuria) compared to placebo.

Proteinuria is an important marker for disease progression in patients with IgA nephropathy, and improvement in proteinuria is associated with improved clinical outcomes. The company says clinical ...

Immunoglobin A nephropathy (also known as IgAN or Berger's disease) is a rare kidney disease that occurs when your immune ...

Renalys Pharma completes patient enrollment in registrational phase III trial of sparsentan for IgA nephropathy in Japan: Tokyo, Japan Friday, January 31, 2025, 18:00 Hrs [IST] Re ...

Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys Pharma") announced today that it has completed patient enrollment for its registrational Phase III clinical trial of sparsentan for the ...